SCHEDULE: SilverArc Capital Management Discloses Tela Bio Stake

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.8% of Tela Bio, Inc.'s Class A Common Stock as of June 30, 2026.

Summary

• SilverArc Capital Management, LLC and Devesh Gandhi (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of Tela BIO, INC. Class A Common Stock.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 2,137,201 shares of Class A Common Stock.
• This represents 4.8% of the total class of securities.
• SilverArc Capital Management, LLC is a Delaware limited liability company, and Devesh Gandhi is a U.S. citizen.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake in the company. The lack of aggressive language suggests a stable investment approach.

Positives

• Significant ownership stake of 4.8% indicates investor confidence in Tela Bio.
• The filing confirms the investment is in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide details on the acquisition cost or the specific investment strategy beyond 'ordinary course of business'.

Risks

• Potential for increased market activity or influence from SilverArc Capital Management if their stake changes significantly in the future.
• The 4.8% stake, while substantial, does not grant controlling interest, meaning strategic decisions remain with the company's board and management.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding Tela Bio's future performance. It solely reports on current beneficial ownership.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates SilverArc Capital Management's strategic interest in Tela Bio within the broader biotechnology and medical device sector.

Stakeholder Impact

• Shareholders: May view the increased stake by a significant investor as a positive signal, potentially leading to increased interest or volatility in the stock price.
• Management and Board: Will be aware of SilverArc Capital Management's substantial holding and may consider their perspective in strategic decision-making.

Next Steps

• Continued monitoring of Tela Bio's stock performance and any subsequent filings by SilverArc Capital Management or other significant shareholders.

Key Dates

Keywords

Tela Bio, SilverArc Capital Management, Devesh Gandhi, Schedule 13G, Beneficial Ownership, Common Stock, Investment Holding